LFMD

Latest SEC Filings & News for LFMD

2 most recent filings and news items mentioning LFMD. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/LFMD/news?limit=20"

Pull LFMD filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

LifeMD Q2 2026 revenue within guidance of $47M-$50M

The company reported $47.3 million in revenue and a gross margin expansion to 89% as it transitions to branded GLP-1 therapies, while reiterating expectations for a return to positive adjusted EBITDA in the second half of 2026.

View filing at SEC.gov →

LifeMD launches exclusive XYOSTED telehealth co-marketing program in July 2026

LifeMD announced an exclusive collaboration with Antares Pharma to offer a direct-to-patient self-pay program for XYOSTED testosterone injection, launching in 37 states at $249/month including care and medication. The partnership leverages LifeMD's virtual care platform and pharm

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.